3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
15
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
4
Myeloid
2
Tumor-Agnostic
1
Other hematologic neoplasm
1
Genitourinary
1
Gastrointestinal
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Azacitidine
160
venetoclax
149
Cytarabine
123
Rituximab
94
fludarabine
76
Cyclophosphamide
70
Imatinib Mesylate
59
nilotinib
55
ibrutinib
54
Dasatinib
48
obinutuzumab
47
Bendamustine Hydrochloride
43
Decitabine
39
Daunorubicin
38
idelalisib
31
acalabrutinib
31
Dexamethasone
29
Chlorambucil
29
Idarubicin
26
gilteritinib
24
Lenalidomide
23
bosutinib
21
asciminib
21
ofatumumab
20
blinatumomab
19
pirtobrutinib
18
fludarabine phosphate
18
Vincristine
18
zanubrutinib
16
ublituximab
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
peginterferon alfa-2b
×
Other hematologic neoplasm
×
Clear all
NCT03547154
2019-08-12
C98026
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
344 enrolled
11 charts